Scarica l'app Stockscreener
140.64
2.60%
3.56
Dopo l'orario di chiusura:
140.60
-0.04
-0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
Piper Sandler Reaffirms "Neutral" Rating for Biogen (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Alberta Investment Management Corp - MarketBeat
Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts - Yahoo Finance
Allianz Asset Management GmbH Has $81.96 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Grows Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Options Trading: A Deep Dive into Market Sentiment - Benzinga
Biogen Inc. (NASDAQ:BIIB) Stock Position Increased by Meitav Investment House Ltd. - MarketBeat
Ieq Capital LLC Buys 55,514 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Stock Is Mutating Into a Value Play - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Sold by ICICI Prudential Asset Management Co Ltd - MarketBeat
What is Wedbush's Forecast for Biogen Q1 Earnings? - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes $751,000 Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
What is William Blair's Estimate for Biogen Q2 Earnings? - MarketBeat
Fenwick Represents Stoke Therapeutics in Strategic Collaboration with BioGen - Fenwick & West LLP
New York State Teachers Retirement System Sells 6,673 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen, Stoke Partner on Zorevunersen in Dravet Syndrome - Contract Pharma
Biogen bags rights to epilepsy drug from Stoke in $550m deal - pharmaphorum
We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative - Simply Wall St
Biogen Inc. (NASDAQ:BIIB) Receives $211.96 Consensus Price Target from Brokerages - MarketBeat
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration - News & Insights
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Oppenheimer maintains Biogen Outperform with $255 target - Investing.com
Biogen stock price target cut to $159 by Bernstein SocGen - Investing.com Australia
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Yahoo Finance
Biogen continues dealmaking buzz with Stoke Therapeutics - The Business Journals
Biogen buys rights to Stoke’s rare epilepsy drug - BioPharma Dive
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - Bloomberg
Bernstein Adjusts Price Target on Biogen to $159 From $160, Keeps Market Perform Rating - Marketscreener.com
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug - STAT
Biogen and Stoke Thera ink deal on zorevunersen development - The Pharma Letter
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
Piper Sandler cuts Biogen price target to $135, keeps neutral rating - Investing.com India
Biogen, Stoke partner for Dravet syndrome treatment - Investing.com
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - MarketWatch
Biogen partners with Stoke Therapeutics on drug for severe epilepsy - STAT
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - Biogen | Investor Relations
Major Epilepsy Treatment Breakthrough: Biogen Acquires Rights to FDA-Designated Therapy in Massive Deal - StockTitan
Biogen's SWOT analysis: stock faces challenges amid pipeline potential - Investing.com
Rhumbline Advisers Has $41.07 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Banque Pictet & Cie SA Raises Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Cantor Fitzgerald Reduces Earnings Estimates for Biogen - MarketBeat
Biogen's (BIIB) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat
Morgan Stanley Has Lowered Expectations for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Acquires New Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
The Goldman Sachs Group Cuts Biogen (NASDAQ:BIIB) Price Target to $245.00 - MarketBeat
Stephens Inc. AR Sells 2,270 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Q1 Earnings Estimate for Biogen Issued By Leerink Partnrs - MarketBeat
19,574 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Strategic Financial Concepts LLC - MarketBeat
Viral Gene Therapy Market May See a Big Move | Biogen, Novartis AG, Gilead Sciences - openPR
Vontobel Holding Ltd. Increases Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Reports Q4 and Full-Year 2024 Results: Strong EPS Growth Amid Revenue Challenges - BSA bureau
Van ECK Associates Corp Purchases 967,523 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wells Fargo & Company Issues Pessimistic Forecast for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
Biogen (NASDAQ:BIIB) Given New $224.00 Price Target at Scotiabank - MarketBeat
Truist Financial Has Lowered Expectations for Biogen (NASDAQ:BIIB) Stock Price - MarketBeat
HC Wainwright Lowers Biogen (NASDAQ:BIIB) Price Target to $241.00 - MarketBeat
0.61%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):